Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
Chiara Agrati, Concetta Castilletti, Delia Goletti, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

The immune response to SARS-CoV-2 in people with HIV
Maxine A. Höft, Wendy A. Burgers, Catherine Riou
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 184-196
Open Access | Times Cited: 29
Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?
Matteo Augello, Valeria Bono, Roberta Rovito, et al.
Current HIV/AIDS Reports (2023) Vol. 20, Iss. 2, pp. 51-75
Open Access | Times Cited: 25
Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines
Paulina Kapłonek, Yixiang Deng, Jessica Shih-Lu Lee, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 5, pp. 101048-101048
Open Access | Times Cited: 21
Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
Alessandra Aiello, Andrea Coppola, Valentina Vanini, et al.
International Journal of Infectious Diseases (2022) Vol. 122, pp. 841-849
Open Access | Times Cited: 29
Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose
Milja Belik, Oona Liedes, Saimi Vara, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose
Luca Perico, Marta Todeschini, Federica Casiraghi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Multi-epitopes vaccine design for surface glycoprotein against SARS-CoV-2 using immunoinformatic approach
Sarmad Frogh Arshad, Rehana Rehana, Muhammad Asif Saleem, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24186-e24186
Open Access | Times Cited: 6
Antibody Responses to mRNA COVID-19 Vaccine Among Healthcare Workers in Outpatient Clinics in Japan
Teruhime Otoguro, Keita Wagatsuma, Teruko Hino, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 90-90
Open Access
Assessing Torquetenovirus (TTV) as a Biomarker for Immune Responses to SARS-CoV-2 mRNA Vaccines in People Living with HIV and Healthy Individuals
Claudia Minosse, Pietro Giorgio Spezia, Valentina Mazzotta, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 153-153
Open Access
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
Alessandra Aiello, Andrea Coppola, Serena Ruggieri, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 94, Iss. 4, pp. 290-299
Open Access | Times Cited: 22
Detailed characterization of SARS-CoV-2-specific T and B cells after infection or heterologous vaccination
Domenico Lo Tartaro, Annamaria Paolini, Marco Mattioli, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Six-month immune responses to mRNA-1273 Vaccine in cART-treated late presenter people living with HIV according to previous SARS-CoV-2 Infection
Matteo Augello, Valeria Bono, Roberta Rovito, et al.
AIDS (2023) Vol. 37, Iss. 10, pp. 1503-1517
Open Access | Times Cited: 11
A longitudinal analysis of humoral, T cellular response and influencing factors in a cohort of healthcare workers: Implications for personalized SARS-CoV-2 vaccination strategies
Eleonora Sabetta, Maddalena Noviello, Clara Sciorati, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Changes in the Adaptive Cellular Repertoire after Infection with Different SARS-CoV-2 VOCs in a Cohort of Vaccinated Healthcare Workers
Sara Caldrer, Silvia Accordini, Cristina Mazzi, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 230-230
Open Access | Times Cited: 3
SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination
Vassiliki Pitiriga, Myrto Papamentzelopoulou, Kanella E. Konstantinakou, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1186-1186
Open Access | Times Cited: 8
Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France
Daisy Graça, Vesna Brglez, Jonathan Allouche, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 8, pp. 1724-1739
Open Access | Times Cited: 7
SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination
Kevin D. Dieckhaus, Min Jung Kim, Jianbing Shen, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 358-358
Open Access | Times Cited: 6
Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV
Alessandra Vergori, Alessandro Cozzi‐Lepri, Giulia Matusali, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1739-1739
Open Access | Times Cited: 6
Improved Performance of the QuantiFERON-SARS-CoV-2 Assay with the Extended Set
Lydia Lamara Mahammed, Kahina Bensaid, Sarah Ait-Seddik, et al.
Viruses (2023) Vol. 15, Iss. 5, pp. 1179-1179
Open Access | Times Cited: 5
Auto-immunoproteomics analysis of COVID-19 ICU patients revealed increased levels of autoantibodies related to the male reproductive system
Frank Schmidt, Houari Abdesselem, Karsten Suhre, et al.
Frontiers in Physiology (2023) Vol. 14
Open Access | Times Cited: 5
Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis
Gianfranco Alicandro, B.S. Orena, Chiara Rosazza, et al.
Vaccine (2023) Vol. 41, Iss. 28, pp. 4114-4120
Open Access | Times Cited: 4
A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2
Takenao Koseki, Mayumi Teramachi, Minako Koga, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1767-1767
Open Access | Times Cited: 4
Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
Thanyawee Puthanakit, Napaporn Chantasrisawad, Kirana Yoohat, et al.
Vaccines (2022) Vol. 10, Iss. 10, pp. 1646-1646
Open Access | Times Cited: 7
A phase I/II clinical trial of intradermal, controllable self-replicating RNA vaccine EXG-5003 against SARS-CoV-2
Takenao Koseki, Mayumi Teramachi, Minako Koga, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in PLWH
Alessandra Vergori, Alessandro Cozzi‐Lepri, Giulia Matusali, et al.
(2023)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top